Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer
Kazuma Fujita, Mitsuji Nagahama, Akifumi Suzuki, Chie Masaki, Kiminori Sugino, Koichi Ito et al. Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer. // Cancer Chemotherapy and Pharmacology. – 2024. – DOI: 10.1007/s00280-024-04729-6. – URL: https://doi.org/10.1007/s00280-024-04729-6
Kazuma Fujita, Mitsuji Nagahama, Akifumi Suzuki, Chie Masaki, Kiminori Sugino, Koichi Ito, & Masatomo Miura (2024). Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04729-6
Kazuma Fujita, et al. “Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer.” Cancer Chemotherapy and Pharmacology, 2024. doi:10.1007/s00280-024-04729-6.
@article{Fujita2024,
title = {Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer},
author = {Fujita, Kazuma and Nagahama, Mitsuji and Suzuki, Akifumi and Masaki, Chie and Sugino, Kiminori and Ito, Koichi and Miura, Masatomo},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-024-04729-6},
url = {https://doi.org/10.1007/s00280-024-04729-6}
}